NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Aquestive Therapeutics, Inc. (AQST) Stock Analysis

Aquestive Therapeutics, Inc. (AQST) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

AQST

$5.34

−$0.01 (−0.19%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare AQST with… →

AQST Key Statistics

As of Sep 4, 2026
Trading
Open
$5.32
Previous Close
$5.35
Day's Range
5.29–5.49
52-Week Range
2.93–7.55
Volume
2.12M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.47
Valuation
Market Cap
$670.23M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
12.39
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.66
Financials (FY)
Revenue (FY)
$44.55M−22.61%
Net Income (FY)
−$83.78M
Profit marginThe share of revenue left as profit after all costs and taxes.
−144.63%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
125.51M
1-Year Return
+5.53%
Dividend and dates
Earnings Date
November 4, 2026
Avg Volume
2.68M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

AQST Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−17.34%
2025+81.46%
2024+76.24%
2023+123.95%
2022−76.81%
2021−27.29%
2020−8.08%
2019−7.62%
2018 (partial year)−60.75%

As of September 4, 2026.

AQST Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$44.55M−$83.78M−188.1%
2024$57.56M−$44.14M−76.7%
2023$50.58M−$7.87M−15.6%
2022$47.68M−$54.41M−114.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$44.55M$25.99M−$71.05M−$83.78M−188.1%
2024$57.56M$39.69M−$30.77M−$44.14M−76.7%
2023$50.58M$29.75M−$15.10M−$7.87M−15.6%
2022$47.68M$28.29M−$42.07M−$54.41M−114.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

AQST Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricAQSTDrug Manufacturers - Specialty & Generic medianvs median
P/S ratio12.392.305.4x the median
Profit margin−144.63%−3.14%141.5 pts below

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Aquestive Therapeutics, Inc. (AQST) carries a market capitalisation of $670.23M. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. Headcount on file is 147.

The 52-week range on file runs from $2.93 to $7.55. AQST last closed at $5.34 on September 4, 2026. That is −$0.01 (−0.19%) against the previous close. The latest close sits 82.25% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $44.55M. That is −22.61% against the prior fiscal year, when revenue was $57.56M. The same year closed with a net loss of $83.78M. Profit margin runs at −144.63%. That is 141.5 percentage points below the Drug Manufacturers - Specialty & Generic median of −3.14%. Earnings per share on a trailing basis come to −0.66.

Across the 4 fiscal years on file, revenue moves from $47.68M in 2022 to $44.55M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 12.39 times revenue. On price-to-sales that is 5.4 times the Drug Manufacturers - Specialty & Generic median of 2.3. The medians here are taken across 103 Drug Manufacturers - Specialty & Generic companies that report the metric.

The trailing one-year price return is +5.53%. Across 5 years the annualized return works out at +3.34%. The reported beta is 1.47. Daily returns over the trailing 8 years annualize to a volatility of 87.45%.

Growth & Income

No dividend is on file for AQST.

Across the complete calendar years on file, 2023 returned +123.95% and 2022 returned −76.81%. Of the 7 complete calendar years on file, 3 finished higher. So far in 2026 the price is −17.34%.

Peer Comparison

Aquestive Therapeutics, Inc. (AQST) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Aquestive Therapeutics, Inc. AQST $670.23M —
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Haleon plc HLN $42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Aquestive Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Visit website →